Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048984 · ClinicalTrials.gov registry record
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
A clinical trial of Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 637
- Enrollment target
- 1
- Study location
NCT00048984 is a study of Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor that has completed, run by Children's Oncology Group. The registered enrollment target is 637 participants, above the 67-participant average among 6 other Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor trials with a reported enrollment target (851% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00048984, a study of Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 637 participants
- Enrollment target
- 1
- Study location
Study Summary
Diagnostic trial to study genetic differences in patients who have Ewing's sarcoma. Genetic testing may help predict how cancer will respond to treatment and allow doctors to plan more effective therapy.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 637 participants |
| Start Date | 2003-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048984
The ClinicalTrials.gov registry entry for NCT00048984 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 637 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 6 other Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor trials with a reported enrollment target (851% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor appearing as the primary indexed condition, and to 1 intervention - of which laboratory biomarker analysis is the first listed.
NCT00048984 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00048984 about?
NCT00048984 is a clinical study titled "Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma". Diagnostic trial to study genetic differences in patients who have Ewing's sarcoma. Genetic testing may help predict how cancer will respond to treatment and allow doctors to plan more effective therapy.
What is the current status of trial NCT00048984?
This trial is currently completed. The enrollment target is 637 participants. The study started on 2003-01.
What conditions does trial NCT00048984 study?
This clinical trial studies the following conditions: Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor.
What interventions are being tested in trial NCT00048984?
The interventions under investigation include: laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT00048984?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048984 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
COMPLETED · Phase 1
-
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
COMPLETED · Phase 2
-
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
All registered trials for this condition
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.